Published in Expert Rev Clin Pharmacol on May 01, 2011
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.81
Personalized medicine and cancer. J Pers Med (2012) 0.80
Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet (2013) 0.80
Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control (2015) 0.77
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Common deletion polymorphisms in the human genome. Nat Genet (2006) 15.66
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol (2010) 5.93
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (2010) 4.73
Identifiability, exchangeability, and epidemiological confounding. Int J Epidemiol (1986) 4.40
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol (2007) 3.42
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol (2001) 2.36
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res (2007) 2.20
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res (1982) 2.15
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci (2008) 1.95
Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer (2007) 1.94
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol (2008) 1.92
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol (2010) 1.66
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65
Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun (1997) 1.63
Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst (2005) 1.60
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol (1996) 1.60
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol (2007) 1.55
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther (2008) 1.53
Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol (2006) 1.51
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) 1.49
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat (1982) 1.48
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst (2011) 1.47
Steroid sulfation by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol (1994) 1.47
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res (1988) 1.45
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat (2009) 1.34
Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics (1997) 1.31
Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat (2007) 1.31
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res (2010) 1.31
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res (2008) 1.28
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol (2002) 1.28
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat (2009) 1.25
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J (2008) 1.23
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer (2008) 1.22
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J (1999) 1.15
Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res (2001) 1.14
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol (2004) 1.09
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol (2010) 1.07
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer (2010) 1.06
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev (2009) 1.06
Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res (2009) 1.06
Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics (2000) 1.05
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res (2011) 1.05
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat (2010) 1.03
No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol (2009) 1.01
Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol (2009) 0.98
The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer (2004) 0.98
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol (2004) 0.98
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci (2009) 0.98
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics (2010) 0.94
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res (2010) 0.92
Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther (2010) 0.91
Phenol sulfotransferase 1A1 activity in human liver: kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem Pharmacol (2003) 0.91
The metabolism of tamoxifen in human. Biochem Pharmacol (1979) 0.90
Modification of tamoxifen response: what have we learned? J Clin Oncol (2008) 0.89
Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat (2010) 0.89
Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin (2010) 0.86
Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. Future Oncol (2010) 0.86
Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA (2010) 0.84
Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer. Cancer Lett (2004) 0.83
Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncol (2008) 0.81
Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat (2010) 0.81
Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas (2005) 0.78
Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br J Clin Pharmacol (2004) 0.76
CYP2D6 testing for breast cancer patients: is there more to the story? Oncology (Williston Park) (2009) 0.75
A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol (2005) 5.17
The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol (2011) 4.54
Breast cancer treatment of older women in integrated health care settings. J Clin Oncol (2006) 3.46
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol (2007) 3.42
Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg (2007) 2.43
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol (2009) 2.33
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol (2002) 2.23
Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol (2011) 2.12
Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer (2007) 1.94
Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology (2006) 1.87
Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol (2003) 1.85
Acute stress reaction and completed suicide. Int J Epidemiol (2010) 1.82
Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol (2002) 1.75
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol (2010) 1.66
Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med (2007) 1.65
What's wrong with the National Ambient Air Quality Standard (NAAQS) for fine particulate matter (PM(2.5))? Regul Toxicol Pharmacol (2002) 1.59
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev (2010) 1.55
Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer (2005) 1.50
Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer (2010) 1.46
Immortal person-time in studies of cancer outcomes. J Clin Oncol (2009) 1.40
Posttraumatic stress disorder and cancer risk: a nationwide cohort study. Eur J Epidemiol (2015) 1.39
Validity of birth certificate-derived maternal weight data. Paediatr Perinat Epidemiol (2014) 1.39
If you want to know the end, look at the beginning. Epidemiology (2015) 1.39
Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol (2007) 1.36
Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology (2008) 1.28
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer (2009) 1.25
Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clin Epidemiol (2010) 1.16
Posttraumatic stress disorder and completed suicide. Am J Epidemiol (2010) 1.14
Increased CUG triplet repeat-binding protein-1 predisposes to impaired adipogenesis with aging. J Biol Chem (2006) 1.13
Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study. BMJ Open (2013) 1.13
Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat (2006) 1.12
Validity of self-reported rheumatoid arthritis in a large cohort: results from the Black Women's Health Study. Arthritis Care Res (Hoboken) (2010) 1.07
Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res (2008) 1.07
Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care (2009) 1.07
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev (2009) 1.06
Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol (2010) 1.06
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol (2010) 1.06
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Breast cancer survival of American Indian/Alaska Native women, 1973-1996. Soz Praventivmed (2005) 1.03
Increased TNFalpha and CCAAT/enhancer-binding protein homologous protein with aging predispose preadipocytes to resist adipogenesis. Am J Physiol Endocrinol Metab (2007) 1.01
Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis (2008) 0.99
A null association between smoking during pregnancy and breast cancer using Massachusetts registry data (United States). Cancer Causes Control (2003) 0.98
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer (2011) 0.97
Determinants and patterns of utilization of primary percutaneous coronary intervention across 12 European countries: 2003-2008. Int J Cardiol (2013) 0.97
Re: "Neighborhood environment and loss of physical function in older adults: evidence from the Alameda County Study". Am J Epidemiol (2003) 0.96
Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study. PLoS One (2013) 0.94
Severe stress and adjustment disorder diagnoses in the population of Denmark. J Trauma Stress (2014) 0.94
Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev (2009) 0.94
Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol (2013) 0.94
Correspondence between general practitioner-reported medication use and timing of prescription dispensation. Clin Epidemiol (2012) 0.93
Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol (2012) 0.92
Delayed radiotherapy for breast cancer patients in integrated delivery systems. Am J Manag Care (2009) 0.92
Modification of tamoxifen response: what have we learned? J Clin Oncol (2008) 0.89
Risk of decline in upper-body function and symptoms among older breast cancer patients. J Gen Intern Med (2006) 0.89
The association between adjustment disorder diagnosed at psychiatric treatment facilities and completed suicide. Clin Epidemiol (2010) 0.89
Specifying exposure classification parameters for sensitivity analysis: family breast cancer history. Clin Epidemiol (2009) 0.89
Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation (2011) 0.89
Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis (2013) 0.89
Trends in breast-conserving surgery in Denmark, 1982-2002. Eur J Epidemiol (2007) 0.88
Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. J Med Econ (2013) 0.87
Lifetime tobacco smoke exposure and breast cancer incidence. Cancer Causes Control (2009) 0.87
Persistent geographical disparities in the use of primary percutaneous coronary intervention in 120 European regions: exploring the variation. EuroIntervention (2013) 0.86
Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res (2012) 0.86
Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. Future Oncol (2010) 0.86
Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J (2007) 0.85
Obesity as a risk factor for severe influenza-like illness. Influenza Other Respir Viruses (2013) 0.85
Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer. Breast Cancer Res Treat (2013) 0.85
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol (2014) 0.85
Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res (2010) 0.85
Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am J Epidemiol (2010) 0.84
Trauma, comorbidity, and mortality following diagnoses of severe stress and adjustment disorders: a nationwide cohort study. Am J Epidemiol (2015) 0.84
Predictors and outcomes of surgeons' referral of older breast cancer patients to medical oncologists. Cancer (2005) 0.84
Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA (2010) 0.84
The primary care pediatrician's influence on medical student's performance of smoking assessments and counseling. Prev Med (2004) 0.84
Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. Cancer (2002) 0.83
Mobile phone use and risk of uveal melanoma: results of the risk factors for uveal melanoma case-control study. J Natl Cancer Inst (2009) 0.83
Mortality in cancer patients with a history of cutaneous squamous cell carcinoma--a nationwide population-based cohort study. BMC Cancer (2012) 0.83
Glyphosate results revisited. Environ Health Perspect (2005) 0.83
Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes (2010) 0.82
NO excess risk of breast cancer among female users of systemic glucocorticoids. Cancer Epidemiol Biomarkers Prev (2005) 0.82
Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat (2014) 0.82
Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study. Breast Cancer Res (2010) 0.81
Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. Cancer Epidemiol Biomarkers Prev (2008) 0.81
Estrogen-related and other disease diagnoses preceding Parkinson's disease. Clin Epidemiol (2010) 0.81
Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer (2006) 0.81
Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.81
Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology (2009) 0.80
Lasagna plots made in different (statistical) ovens. Epidemiology (2012) 0.80
Cognitive test scores in young men and subsequent risk of type 2 diabetes, cardiovascular morbidity, and death. Epidemiology (2013) 0.80
Risk factor studies of age-at-onset in a sample ascertained for Parkinson disease affected sibling pairs: a cautionary tale. Emerg Themes Epidemiol (2007) 0.80
Inflammatory bowel disease and completed suicide in Danish adults. Inflamm Bowel Dis (2010) 0.80
Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncol (2011) 0.79
Birth outcome in Danish women with cutaneous malignant melanoma. Melanoma Res (2007) 0.79
Potential misinterpretations caused by collapsing upper categories of comorbidity indices: An illustration from a cohort of older breast cancer survivors. Clin Epidemiol (2009) 0.79
Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol (2010) 0.79
Validating medical students' self-report of smoking-related communication skills and educational experiences. Ambul Pediatr (2007) 0.78